2 июл. 2024 г. · Kisunla is the first and only amyloid plaque-targeting therapy that used a limited-duration treatment regimen based on amyloid plaque removal.

This is the first Phase 3 trial of any investigational medicine for Alzheimer's disease to deliver 35% slowing of clinical and functional ...

2 июл. 2024 г. · The drug, donanemab, to be sold under the brand name Kisunla, was shown in studies to modestly slow the pace of cognitive decline in early stages of the ...

3 июл. 2024 г. · As of July 2, the FDA has approved donanemab for adults with early symptomatic Alzheimer's disease, mild cognitive impairment, and mild dementia ...

Donanemab contains antibodies that bind to a protein called amyloid, which builds up in the brain in the early stages of Alzheimer's disease.

2 июл. 2024 г. · Donanemab, made by Indianapolis-based Eli Lilly, works by helping the body remove amyloid plaque buildup in the brain, a hallmark of Alzheimer's ...

23 окт. 2024 г. · Donanemab could slow down cognitive decline by 4-7 months, but this is just not enough benefit to justify the additional cost to the NHS.

2 июл. 2024 г. · Eli Lilly's drug slowed Alzheimer's progression by 35% over 18 months compared with a placebo, according to a late-stage trial. Patients were ...

30 окт. 2024 г. · Eli Lilly has shared positive results from a late-stage study of its amyloid plaque-targeting Alzheimer's disease (AD) drug donanemab in ...

11 июн. 2024 г. · A new Alzheimer's drug developed by Eli Lilly, called donanemab, is effective and that the benefits of the medication outweigh its risks.